Alliance Global Partners lowered the firm’s price target on Journey Medical (DERM) to $10 from $10.50 and keeps a Buy rating on the shares following the Q1 report. The firm adjusted its model lower due to Journey’s legacy business trends.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM: